Aaron Lisberg - Concepedia

Author

Aaron Lisberg

University of California, Los Angeles ORCID

Also Known As

A Lisberg, A. Lisberg, A.E. Lisberg, Aaron E Lisberg, Aaron E. Lisberg, Aaron Elliott Lisberg, Aaron Lisberg, Lisberg, Aaron, William Lawler

188

Publications

9.8K

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles Daiichi Sankyo (United States)Dana-Farber Cancer Institute Massachusetts General Hospital The University of Texas MD Anderson Cancer Center

About

Aaron Lisberg is an author at University of California, Los Angeles specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	26	7.8K
2	Health Sciences	6	6	5.6K
3	Natural Sciences	1	1	24
4	Allergy	1	1	14
5	Biostatistics	1	1	49

Aaron Lisberg

Publications

9.3K

Citations

H-Index

Page 1

	Year	Citations
RETRACTED ARTICLE: Pluripotency of mesenchymal stem cells derived from adult marrow Yuehua Jiang, Balkrishna Jahagirdar, R. Lee Reinhardt, Nature Regenerative MedicineMesenchymal Stem CellsInduced Pluripotent Stem CellDevelopmental BiologyAdult Marrow	2002	5.5K
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial Narek Shaverdian, Aaron Lisberg, Krikor Bornazyan, The Lancet Oncology Radiation MedicineRadiation TherapyMedicinePathologyKeynote-001 Phase 1	2017	1.1K
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC Aaron Lisberg, Amy L. Cummings, Jonathan W. Goldman, Journal of Thoracic Oncology Advanced NsclcOncologyMedicineReceptor Tyrosine KinasePhase Ii Study	2018	577
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer Katherine Hastings, Helena A. Yu, Wen Wei, Annals of Oncology	2019	352
Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study Kelly G. Paulson, Christopher W. Lewis, Mary W. Redman, Cancer	2016	175
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01 Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, Journal of Clinical Oncology	2023	141
Spatial mapping of mitochondrial networks and bioenergetics in lung cancer Mingqi Han, Eric A. Bushong, Mayuko Segawa, Nature	2023	131
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares, Journal of Clinical Oncology	2024	130
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study Aditya Bardia, Ian E. Krop, Takahiro Kogawa, Journal of Clinical Oncology	2024	124
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center Aaron Lisberg, D. Andrew Tucker, Jonathan W. Goldman, Cancer Immunology Research	2018	102

Page 1